Lisdexamfetamine

Includes cardiomyopathy, serious cardiac arrhythmias, coronary artery disease, and other structural heart defects. FDA prescribing information lists as absolute contraindication.

FDA prescribing information lists as contraindication. Blood pressure must be assessed before initiation and monitored during treatment.

Pre-existing tic disorders including Tourette syndrome are a relative contraindication. Monitor for tic emergence or worsening.

Patients with epilepsy or history of seizures should be monitored. Risk is dose-dependent and increases at supratherapeutic doses.

Undiagnosed or comorbid bipolar disorder increases risk of treatment-emergent mania. Psychiatric screening recommended before initiation.

Personal or family history of psychosis is a relative contraindication. Screening recommended before initiation. New-onset psychotic symptoms documented in post-marketing surveillance.

FDA prescribing information lists as contraindication.

FDA prescribing information lists as contraindication due to additive sympathomimetic activation.

Use during pregnancy only if potential benefit justifies potential risk to the fetus. Limited human data available.

Standard drug allergy contraindication per FDA prescribing information.

Absolute contraindication per FDA prescribing information. A 14-day washout period is required after MAOI discontinuation before initiating LDX. Case report documents hypertensive emergency with ST-elevation MI from MAOI + amphetamine combination.

FDA prescribing information lists as contraindication. Applies specifically to narrow-angle (angle-closure) glaucoma.